GLP-1 Drugs & Mental Health: Risks, Interactions, and What You Need to Know

Medication Safety

GLP-1 Drugs and Mental Health: What the Evidence Says About Depression Risk, Your Psychiatric Medications, and the Screening Almost Nobody Does

Regulators on two continents looked hard for a link between these drugs and suicidal thinking, and didn't find one. That's the reassuring part. The part nobody is talking about is what happens when a GLP-1 meets lithium, an antipsychotic, or an eating disorder history that was never asked about.

Reviewed by the clinical team at East Coast Telepsychiatry  |  Evidence-based patient education  |  Reading time: 14 minutes

If you take a psychiatric medication and you've thought about asking for a GLP-1 — semaglutide, tirzepatide, liraglutide, whatever the name on the pen — you have probably already been handed two unhelpful answers. One is that these drugs cause depression and suicidal thoughts, which the best available evidence does not support. The other is that they're essentially risk-free, which is also wrong, just in a quieter and more specific way.

The real risks for someone on psychiatric medication aren't the ones that made headlines. They're pharmacological and procedural: a mood stabilizer whose blood level can climb into toxicity when GI side effects hit, oral medications whose absorption nobody has properly studied, and an eating disorder screening step that an international expert panel says should happen before the first dose and very often doesn't.

This article covers both halves honestly — the reassurance and the gaps — because the people most likely to be prescribed these drugs include a very large number of people whose psychiatric medications caused the weight gain in the first place.

No causal linkEuropean regulator's 2024 conclusion on GLP-1 drugs and suicidal thoughts 10–15 yrsLife expectancy gap in severe mental illness, driven largely by metabolic disease 94.7%Expert agreement that every patient should be screened for eating disorders first ZeroPublished studies on how GLP-1 drugs affect absorption of oral antipsychotics

Do GLP-1 Drugs Cause Depression or Suicidal Thoughts?

Short answer

The evidence says no. After a safety signal emerged in 2023, both the FDA and the European Medicines Agency investigated. The EMA's safety committee concluded in April 2024 that there is no causal association between GLP-1 receptor agonists and suicidal thoughts or self-harm, and that no labeling change was warranted. The FDA's preliminary review reached the same conclusion. A January 2024 Nature Medicine study of over 240,000 patients found GLP-1 use was associated with a lower likelihood of suicidal ideation, not a higher one.

The story is worth understanding, because it's a clean example of how a safety signal gets investigated and how easily a headline outlives its own retraction.

In 2023, a small number of post-marketing reports of suicidal thinking in people taking semaglutide and liraglutide prompted regulators to look. The EMA's Pharmacovigilance Risk Assessment Committee reviewed case reports, its own study, a Nature Medicine analysis of more than 240,000 patients with overweight or obesity, and a separate analysis of nearly 1.6 million people with type 2 diabetes. In April 2024 it concluded there was no causal association, while asking manufacturers to keep monitoring. A nationwide Danish case-time-control study published in eClinicalMedicine came to a similar place.

Two caveats keep this honest. First, "no causal association at a population level" is not the same as "this cannot happen to you" — individual reactions to any drug exist, and if your mood changes meaningfully after starting one, that is worth reporting rather than dismissing. Second, some of the observational findings pointing the other direction — that GLP-1 use was associated with lower rates of suicidal ideation, substance-related disorders, and even dementia in large records-based studies — are also observational. They are reassuring, but they are not proof of benefit, and researchers who have published them say so explicitly.

Why Are Psychiatrists Suddenly Interested in These Drugs?

Short answer

Because psychiatric medication is one of the leading causes of the metabolic problems these drugs treat. People with severe and persistent mental illness die 10 to 15 years earlier than the general population, and the gap is driven mostly by cardiovascular and metabolic disease rather than by psychiatric illness itself. Several antipsychotics — olanzapine and clozapine most of all — cause rapid, substantial weight gain. A drug that could offset that is not a cosmetic question.

This is the part of the GLP-1 conversation that gets almost no public attention, and it's arguably the most important.

Weight gain from antipsychotics is not a minor inconvenience. It's a major driver of the mortality gap in serious mental illness, and it's one of the most common reasons people stop taking medication that was otherwise working — which then costs them the psychiatric stability the medication was providing. A 2026 review in The Canadian Journal of Psychiatry by Jacobson, Margolese and Margolese laid out the case for GLP-1 receptor agonists as a response to exactly this problem.

The psychiatric trial evidence is early but encouraging. The COaST trial studied semaglutide in people with schizophrenia taking clozapine over 36 weeks — a small study, 31 participants — and found meaningful weight reduction (13.88% versus 0.42% on placebo) without worsening psychotic symptoms and without altering clozapine blood levels. A Canadian case series of 12 patients who hadn't responded to metformin found a mean reduction of 8.67 kg over twelve months. An earlier systematic review found liraglutide produced a mean reduction of 4.70 kg over 12 to 24 weeks, while exenatide's effect was not statistically significant.

Those are small numbers of people. They are also the first real signal that a problem psychiatry has struggled with for thirty years might have a pharmacological answer.

The most consequential GLP-1 questions for someone on psychiatric medication are about drug interactions and monitoring — not about the headlines.

Can You Take a GLP-1 Alongside Psychiatric Medication?

Short answer

Usually yes, but the monitoring matters and it varies a lot by medication. Lithium is the clearest concern: GI side effects can cause dehydration that raises lithium levels toward toxicity, and published case reports describe exactly that after starting semaglutide. Oral medications in general may be affected by slowed stomach emptying, and for oral antipsychotics specifically there is essentially no published data. None of this is a reason not to proceed — it's a reason to proceed with a prescriber who is paying attention.

Medication	What to watch for	Practical implication
Lithium	Vomiting, diarrhea, and reduced fluid intake can concentrate lithium in the blood. Case reports describe toxicity and altered clearance after starting semaglutide	Levels should be checked before starting and again after each dose increase, plus any time GI side effects are significant. Hydration matters more than usual
Oral antipsychotics	Slowed gastric emptying could in principle alter absorption. The 2026 Canadian review found no published studies on this	Worth monitoring symptoms closely during dose escalation. For clozapine, the COaST trial found no change in levels — a reassuring but single data point
Lithium's cousins — valproate, carbamazepine	Less documented interaction risk, but GI side effects can still affect adherence and absorption	Standard level monitoring becomes more valuable, not less, during the first months
Antidepressants (SSRIs, SNRIs)	No established pharmacokinetic interaction. Overlapping nausea is the main practical issue, since both can cause it	Starting both at once makes it hard to tell what's causing what. Staggering is often sensible
Stimulants (ADHD)	Both can suppress appetite. Combined effect on intake can be more than either alone	Worth explicitly tracking that you're eating enough, not just less

If You Take Lithium, Read This Part Twice

Lithium has a narrow therapeutic window — the gap between an effective level and a toxic one is small — and it's cleared by the kidneys in a way that depends heavily on hydration and sodium balance. GLP-1 drugs commonly cause nausea, vomiting, and diarrhea, particularly while the dose is being increased, and they reduce appetite including for fluids.

Put those two facts together and you get a predictable problem. A Mayo Clinic case series published in the Journal of Clinical Psychopharmacology documented lithium toxicity and altered lithium clearance in patients with bipolar disorder after starting semaglutide. A separate case report describes toxicity following a switch from semaglutide to tirzepatide.

This is manageable — it is a monitoring problem, not a prohibition. But it requires that whoever prescribes the GLP-1 knows you're on lithium, and that whoever manages your lithium knows you've started a GLP-1. When those are two different clinicians who don't talk to each other, this is exactly the gap things fall through. Symptoms of lithium toxicity — worsening tremor, confusion, unsteadiness, slurred speech, persistent vomiting — warrant same-day medical attention, not a wait-and-see.

Should You Be Screened for an Eating Disorder First?

Short answer

Yes, and an international expert panel now says so formally. A consensus statement published in World Psychiatry in 2026 — 45 experts across obesity medicine, eating disorder care, and lived experience — recommended with 94.7% agreement that every patient be assessed for current or past eating disorders before starting a GLP-1, using a brief three-to-five-question screen, in whatever setting is prescribing, including primary care. Agreement was unanimous that active anorexia nervosa or bulimia with marked restriction should generally be a reason not to prescribe.

This recommendation exists because the prescribing has run far ahead of the screening. GLP-1s are now prescribed at enormous scale through primary care, telehealth platforms, and med spas, and a brief eating disorder history is not a standard part of most of those encounters. Meanwhile the panel noted reports of relapse and of new eating disorders emerging during treatment, and identified understanding that risk as a major research gap.

The panel was also candid in the other direction, which makes the statement more credible rather than less. On the question of whether GLP-1s help binge eating disorder — a popular claim — they noted that the most rigorously controlled trial found no greater reduction in binge frequency than placebo, despite greater weight loss. The evidence base outside of binge eating disorder they described as limited and inconsistent.

If you have any history here — a past diagnosis, a period of restriction, a complicated relationship with eating that you've never named to a clinician — it is worth raising before starting rather than after. Not because it necessarily rules anything out; the panel was explicit that a positive screen should prompt closer monitoring or specialist referral rather than an automatic no. But because a drug that suppresses appetite lands very differently on that history, and the person prescribing it should know.

What About Alcohol and Addiction?

Short answer

This is the most interesting open question in the field. A randomized placebo-controlled trial published in JAMA Psychiatry in 2025 found that low-dose semaglutide reduced alcohol craving, drinks per drinking day, and heavy drinking days over nine weeks in 48 adults with alcohol use disorder — with a signal on cigarettes in a small subgroup of smokers. It is a genuinely promising early result and nothing more than that. Semaglutide is not an approved treatment for alcohol use disorder.

The trial, led by Christian Hendershot with senior author Klara Klein at UNC, was small, short, and conducted in people who were not actively seeking treatment for their drinking. The researchers were unusually clear about its limits: results are preliminary, long-term effects are unknown, the right dose and duration are unclear and may differ from what's used for diabetes or weight, and the mechanism is not understood beyond preclinical work suggesting effects on reward processing in the brain. A larger trial in people with alcohol use disorder and comorbid obesity has since been published in The Lancet.

If you have a drinking problem, the honest read is this: there are treatments for alcohol use disorder with real evidence behind them right now — naltrexone, acamprosate, and structured behavioral treatment among them — and none of them require you to wait for a research program to mature. A GLP-1 is not yet one of those treatments.

9 Questions Worth Bringing to Your Prescriber

1. Does whoever prescribes this know my full psychiatric medication list? Including doses, and including anything I take occasionally.
2. If I'm on lithium, when will my level be checked? Before starting and after each increase is the answer you want to hear.
3. Who is coordinating between my prescribers? If the answer is "you are," ask for that to be written down somewhere both of them can see.
4. Have you asked me about eating disorder history? If they haven't, raise it yourself.
5. What side effects should make me call rather than wait? Persistent vomiting matters more for some patients than others.
6. How will we tell drug side effects apart from my psychiatric symptoms? Nausea, low appetite, fatigue, and low mood overlap substantially.
7. What's the plan if I stop? Weight regain after discontinuation is common, which makes this a long-term decision.
8. Is my psychiatric condition currently stable enough for a new variable? Mid-crisis is rarely the moment to add one.
9. What does this cost after the first few months? Coverage for these drugs is inconsistent and changes.

Most of the risk in combining a GLP-1 with psychiatric medication is coordination risk — two prescribers who each know half the picture.

What the Evidence Does Not Yet Show

Short answer

Four things, specifically: how these drugs affect absorption of oral antipsychotics; whether the apparent benefits in mental health seen in observational records are real or an artifact of who gets prescribed them; what years of continuous use does; and whether they help eating disorders, where the best-controlled trial was negative. Anyone who tells you these are settled is overselling.

The Honest Gaps

Oral antipsychotic absorption Slowed gastric emptying is a plausible mechanism for altered drug absorption, and the 2026 review found no published studies examining it. Clozapine levels were unchanged in one small trial. The "mental health benefit" signal Large records-based studies link GLP-1 use to lower rates of suicidal ideation, substance disorders, and dementia. Observational data can't establish cause, and the authors say so. Long-term use Stopping typically means regaining weight, which implies indefinite use. The trials behind these drugs ran months to a couple of years, not decades. Eating disorder treatment Despite popular claims, the most rigorous trial found no greater reduction in binge frequency than placebo. Evidence beyond binge eating disorder is thin and inconsistent.

Naming gaps is not the same as counseling against treatment. For many people — especially those carrying metabolic consequences of psychiatric medication — the case for trying one of these drugs is strong. The point is that "strong case" and "fully characterized" are different things, and you're entitled to know which one you're being offered.

Where to Find Reliable Information

• EMA — PRAC meeting highlights, 8–11 April 2024, where the European regulator announced its conclusion on the suicidality question.
• FDA's concerns with unapproved GLP-1 drugs used for weight loss, including compounded and counterfeit products.
• NIMH — Mental Health Medications, for background on the psychiatric drugs involved.
• National Alliance for Eating Disorders — helpline staffed by licensed clinicians at 1-866-662-1235.
• SAMHSA National Helpline — free, confidential, 24/7 treatment referral at 1-800-662-4357.

Frequently Asked Questions

Will Ozempic make my depression worse?

The population-level evidence says no — both the FDA and the EMA investigated and found no causal link, and a 240,000-patient analysis found lower rather than higher rates of suicidal ideation. That said, any new medication can affect how you feel, and the overlap between GLP-1 side effects and depressive symptoms (fatigue, low appetite, nausea) can genuinely muddy the picture. If your mood shifts after starting, that's worth a conversation rather than an assumption in either direction.

I gained a lot of weight on my antipsychotic. Is a GLP-1 an option?

It's an increasingly discussed one, and the clinical literature has moved in that direction — a 2026 review in The Canadian Journal of Psychiatry makes the case directly, and the COaST trial found meaningful weight reduction in people on clozapine without worsening psychotic symptoms. It's a real conversation to have with your prescriber. Metformin is also an established option for antipsychotic-associated weight gain and is often tried first.

Do I need to stop my antidepressant to take a GLP-1?

No. There's no established pharmacokinetic interaction between GLP-1 drugs and SSRIs or SNRIs. The practical issue is that both can cause nausea, so starting them simultaneously makes it hard to attribute side effects. Many prescribers prefer to stagger the start for that reason alone.

Can my psychiatrist prescribe a GLP-1?

Scope varies by clinician and practice. Many psychiatric practices, including ours, don't prescribe GLP-1 drugs and instead coordinate with the primary care clinician or endocrinologist who does. What a psychiatric prescriber should absolutely be doing is reviewing your psychiatric medications in light of the new drug, adjusting monitoring — lithium levels especially — and helping distinguish side effects from symptoms.

Are compounded GLP-1s from telehealth companies safe?

Compounded versions don't undergo FDA review for safety, effectiveness, or quality, and the FDA has issued warnings about semaglutide-containing products including counterfeits and dosing errors. For someone on lithium or an antipsychotic, the bigger issue is often that these prescribing channels frequently involve no coordination with your psychiatric care at all — which is where the interaction risks described above actually materialize.

Will a GLP-1 help my binge eating?

The claim is widespread; the evidence is weaker than the claim. The 2026 World Psychiatry consensus noted that the most rigorously controlled trial found no greater reduction in binge frequency than placebo, despite greater weight loss. Binge eating disorder has treatments with stronger evidence behind them, and it's worth pursuing those on their own terms rather than hoping a weight medication addresses them indirectly.

If You Need Help Right Now

If you're having thoughts of harming yourself, call or text 988 to reach the Suicide & Crisis Lifeline, available 24/7 across the United States, or chat at 988lifeline.org. If you're in immediate danger, call 911 or go to your nearest emergency department.

If you're struggling with eating, restriction, or your relationship with food — whether or not you've ever had a diagnosis — the National Alliance for Eating Disorders helpline is staffed by licensed clinicians at 1-866-662-1235.

A Practical First Step

Before adding any new medication to a psychiatric regimen, it helps to have a clear baseline of where your symptoms actually sit — so that if something shifts in two months, you can tell whether it shifted. Our free, confidential screening tools include the PHQ-9 for depression, the GAD-7 for anxiety, and the MDQ for bipolar features, all of which are more useful repeated over time than taken once.

A screening isn't a diagnosis. It's a number you can compare against a later number.

What We Do and Don't Do Here

East Coast Telepsychiatry does not prescribe GLP-1 drugs. What we do is the psychiatric side of this picture, which is the side most likely to be overlooked: reviewing your psychiatric medications in light of a GLP-1 you're starting or already taking, adjusting monitoring where it matters — lithium levels above all — helping distinguish medication side effects from psychiatric symptoms, and communicating with the clinician who is prescribing the GLP-1 so that neither of us is working from half the chart.

If your weight gain came from a psychiatric medication, there's also a prior question worth asking: whether that medication is still the right one for you, or whether an alternative with a different metabolic profile would work as well. That's a conversation about your diagnosis and treatment rather than about adding a second drug, and it sometimes turns out to be the better route. You can see who our providers are and what care costs before booking anything.

Related Reading

Conditions We TreatDepression, anxiety, bipolar disorder, ADHD, PTSD and more Free ScreeningsPHQ-9, GAD-7, MDQ and other validated self-assessments Our ProvidersBoard-certified psychiatric clinicians across the East Coast Insurance & CostWhat's covered and what care actually costs FAQsHow telepsychiatry works, start to finish More ArticlesEvidence-based mental health education

Two Prescribers Should Not Be Guessing About Each Other

If you're starting a GLP-1, already on one, or weighing whether the psychiatric medication behind your weight gain is still the right choice — that deserves a real medication review, not a note passed between offices.

Schedule a Medication Review Explore Support Options

Sources & Further Reading

1. European Medicines Agency. PRAC meeting highlights, 8–11 April 2024 — the conclusion of no causal association: no causal association with suicidal thoughts or self-harm.
2. European Medicines Agency. Final study report: Suicidal ideation and GLP-1 receptor agonists — the regulator's own study, April 2024.
3. BioSpace. "EMA Finds No Link Between GLP-1 Drugs and Suicidal Thoughts, Self-Harm" — summary of the PRAC review and the parallel FDA investigation.
4. "Suicide and suicide attempt in users of GLP-1 receptor agonists: a nationwide case-time-control study." eClinicalMedicine.
5. Jacobson S, Margolese N, Margolese HC. "GLP-1 Receptor Agonists as a Novel Solution for Antipsychotic-Induced Weight Gain in Severe and Persistent Mental Illness." The Canadian Journal of Psychiatry, 2026;71(6):413–419.
6. "Effect of Semaglutide on Antipsychotic-Induced Weight Gain and Other Metabolic Parameters Among a Cohort of Inpatients." Schizophrenia Bulletin.
7. Keshen A, et al. Eating disorders in the GLP-1 era — emerging clinical risks and practice priorities; international consensus recommendations published in World Psychiatry 2026;25(3):465–474.
8. News-Medical. "Experts call for eating-disorder screening before GLP-1 treatment" — summary of the 45-expert consensus panel, September 2026.
9. UNC Health. "Semaglutide Shows Promise in Reducing Cravings for Alcohol, Heavy Drinking" — the JAMA Psychiatry randomized trial, February 2025.
10. "Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial." The Lancet.
11. Mayo Clinic. "Lithium Toxicity and Altered Clearance Following Initiation of Semaglutide in Patients With Bipolar Disorder: A Case Series and Literature Review." Journal of Clinical Psychopharmacology.
12. "Lithium toxicity following a change from semaglutide to tirzepatide for weight loss management" — case report, PubMed Central.
13. U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss — compounding and counterfeit warnings.

This article is for general educational purposes and does not constitute medical advice, diagnosis, or treatment, and nothing in it is a recommendation for or against any medication. GLP-1 receptor agonists are prescription drugs with real risks and contraindications; decisions about starting, combining, or stopping any medication belong with the clinicians who know your full history. Do not change a prescribed medication on your own. East Coast Telepsychiatry does not prescribe GLP-1 receptor agonists. If you are experiencing a mental health emergency, call or text 988 or dial 911.